眼科用医薬品の市場規模、シェア、成長分析：製品別、剤形別、薬剤クラス別、地域別- 産業予測、2024年～2031年

眼科用医薬品の世界市場規模は、2022年に309億米ドルと評価され、予測期間（2024年～2031年）のCAGRは7.8%で、2023年の333億1,000万米ドルから2031年には607億5,000万米ドルに成長する見通しです。

眼科用医薬品市場は、研究開発努力の増加、主要業界企業の戦略的イニシアティブ、眼科領域におけるアンメットメディカルニーズなどが成長の原動力となっています。推定22億人が視力障害を経験しており、そのうち約10億人が適切な治療で予防可能であることから、市場拡大の大きなチャンスがあります。加齢に関連する疾患は失明や視力喪失の主な原因であり、個人に影響を及ぼすだけでなく、政府にも大きな財政負担を強いています。例えば、近視関連の視力障害だけでも約2,440億米ドルの費用がかかっています。このような目に関連する問題の高い蔓延は、眼科用医薬品の需要を促進すると予想されます。COVID-19パンデミックは眼科用医薬品市場に悪影響を及ぼし、視野検査（93.84%）、診察（92.52%）、投薬（19.63%）、手術（72.74%）の大幅な減少につながった。この減少は、緑内障やその他の眼疾患の治療が減少していることを示しています。しかし、COVID-19ワクチン接種の普及と症例の減少により、市場は回復すると予想されます。大手企業による研究開発投資の増加は、今後数年間の成長を促進すると思われます。例えば、アルコンは研究開発費を2020年の6億7,300万米ドルから2021年には8億4,200万米ドルに引き上げ、コンタクトレンズ、白内障治療、緑内障ソリューションなどの製品に注力しています。さらに、2029年までに発売が予定されているNicoxのNCX 470のような有望な薬剤の強力なパイプラインや、Novartis PharmaceuticalsやAmring Pharmaceuticalsのような企業の戦略的な動きは、市場の成長をさらに促進すると思われます。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 市場の成功要因
• 競合の程度
• 主な投資機会
• 市場魅力度指数
• エコシステムマッピング
• 技術分析
• コスト分析
• 市場動向分析
• 競合分析
• サプライチェーン分析
• 投資分析
• アプリケーション固有の分析
• 特許分析
• 貿易分析
• ケーススタディ分析

眼科用医薬品市場：製品別

• 市場概要
• 処方薬
• 市販薬

眼科用医薬品市場：薬剤クラス別

• 市場概要
• 抗アレルギー、抗炎症
  • 非ステロイド薬
  • ステロイド薬
• 抗VEGF剤
• 緑内障予防
• 遺伝子・細胞治療
• その他

眼科用医薬品市場：疾患別

• 市場概要
• ドライアイ
• アレルギー
• 緑内障
• 感染
• 網膜疾患
  • 黄斑変性症
  • 糖尿病網膜症
• ぶどう膜炎
• その他

眼科用医薬品市場：投与経路別

• 市場概要
• 外用
• 眼の局部
  • 網膜疾患
  • 結膜下
  • 硝子体内
  • 球後部
  • 前房内
• 全身的

眼科用医薬品市場：剤形別

• 市場概要
• ジェル
• 眼科用ソリューションおよび懸濁液
• カプセルと錠剤
• 目薬
• 軟膏

眼科用医薬品市場：タイプ別

• 市場概要
• ブランド医薬品
• ジェネリック医薬品

眼科用医薬品市場：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Novartis AG（Switzerland）
• Roche Holding AG（Switzerland）
• Pfizer Inc.（US）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Bayer AG（Germany）
• Johnson & Johnson（US）
• Merck & Co., Inc.（US）
• Bausch Health Companies Inc.（Canada）
• Alcon, Inc.（Switzerland）
• GlaxoSmithKline plc（UK）
• Eli Lilly and Company（US）
• Regeneron Pharmaceuticals, Inc.（US）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• Aerie Pharmaceuticals, Inc.（US）
• Carl Zeiss Meditec AG（Germany）
• Topcon Corporation（Japan）
• Senju Pharmaceutical Co., Ltd.（Japan）
• AbbVie Inc.（US）
• UCB S.A.（Belgium）
• Hikma Pharmaceuticals PLC（UK）
• Lupin Pharmaceuticals, Inc.（India）
• Tarsus Pharmaceuticals, Inc.（US）

Global Ophthalmic Drugs Market size was valued at USD 30.90 Billion in 2022 and is poised to grow from USD 33.31 Billion in 2023 to USD 60.75 Billion by 2031, at a CAGR of 7.8% during the forecast period (2024- 2031).

The ophthalmic drugs market is poised for growth driven by increased research and development efforts, strategic initiatives from major industry players, and unmet medical needs within the field of ophthalmology. With an estimated 2.2 billion people experiencing vision impairment, including around 1 billion cases that could be prevented with proper treatment, there is a significant opportunity for market expansion. Age-related conditions are a primary cause of blindness and vision loss, which not only affects individuals but also imposes a substantial financial burden on governments. For instance, myopia-related vision impairment alone costs approximately USD 244 billion. This high prevalence of eye-related issues is expected to drive demand for ophthalmic drugs. The COVID-19 pandemic adversely impacted the ophthalmic drugs market, leading to substantial reductions in visual field checkups (93.84%), clinical visits (92.52%), medication releases (19.63%), and surgical procedures (72.74%). This decline indicates a reduction in the treatment of glaucoma and other eye disorders. However, with the advent of widespread COVID-19 vaccination and a decrease in cases, the market is anticipated to recover. Increased R&D investments by major companies are likely to fuel growth in the coming years. For instance, Alcon raised its R&D expenditure from USD 673 million in 2020 to USD 842 million in 2021, focusing on products like contact lenses, cataract treatments, and glaucoma solutions. Additionally, a strong pipeline of promising drugs, such as Nicox's NCX 470, expected to launch by 2029, and strategic moves by companies like Novartis Pharmaceuticals and Amring Pharmaceuticals, are likely to further drive market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ophthalmic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ophthalmic Drugs Market Segmental Analysis

The global ophthalmic drugs market is segmented based on drug class, drug disease, drug dosage, drug route of administration, dosage type, product type and region. Based on product, the market is segmented into prescription durgs, OTC drugs. Based on drug class, the market is segmented into Anti-allergy, Anti-inflammatory (Non-steroidal drugs, Steroidal drugs), Anti-VEGF Agents, Anti-glaucoma, Gene and Cell Therapy, Others. Based on drug disease, dry eye, allergies, glaucoma, infection, retinal disorders, uveitis, others. Based on dosage form market is segmented into, gels, eye solutions and suspensions, capsules and tablets, eye drops, ointments, others. Based on drug route of administration market is segmented into, topical local ocular systemic. Based on type, the market is segmented into branded drugs, generic drugs. Based on Region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Ophthalmic Drugs Market

The growing prevalence of eye conditions such as cataracts, glaucoma, and macular degeneration is a major factor propelling the ophthalmic drugs market. Contributing to this rise are the aging population, shifts in lifestyle, and the increasing occurrence of chronic health issues, all of which amplify the need for effective ophthalmic treatments. As these eye diseases become more common, the demand for ophthalmic drugs is expected to increase correspondingly. The aging demographic, combined with modern lifestyle changes and the prevalence of chronic conditions, highlights the need for enhanced medical solutions to address these vision-related challenges.

Restraints in the Global Ophthalmic Drugs Market

The steep costs associated with ophthalmic drugs and treatments can act as a significant barrier, especially in developing regions where healthcare budgets are constrained and affordability is a major issue. The expenses involved in drug development, production, and distribution contribute to the overall high price of treatments, limiting access for certain patient groups. These financial challenges can impede the availability of essential ophthalmic care in less affluent areas, where limited resources and lower healthcare funding make it difficult for patients to afford necessary treatments. As a result, the high costs of ophthalmic therapies continue to be a critical factor affecting their accessibility and uptake in economically disadvantaged regions.

Market Trends of the Global Ophthalmic Drugs Market

The ophthalmic drugs market is increasingly moving toward personalized medicine, emphasizing treatments that are customized based on individual patient characteristics. This shift is driven by advancements in genomic research and precision medicine, which facilitate the creation of targeted therapies that enhance treatment efficacy and patient satisfaction. These developments allow for more precise and individualized approaches to eye care, improving therapeutic outcomes by tailoring treatments to each patient's unique genetic and clinical profile. This trend towards personalized ophthalmic therapies reflects a broader movement within the medical field to offer more effective and patient-centric treatment options.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors of The Market
• Degree Of Competition
• Top Investment Pockets
• Market Attractive Index
• Ecosystem Mapping
• Technology Analysis
• Cost Analysis
• Market Trend Analysis
• Competition Analysis
• Supply chain analysis
• Investment Analysis
• Application-Specific Analysis
• Patent analysis
• Trade analysis
• Case study analysis

Ophthalmic Drugs Market by Products

• Market Overview
• Prescription Drugs
• OTC Drug

Ophthalmic Drugs Market by Drug Class

• Market overview
• Anti-allergy, Anti-inflammatory
  • Non-steroidal drugs
  • Steroidal drugs
• Anti-VEGF Agents
• Anti-glaucoma
• Gene and Cell Therapy
• Others

Ophthalmic Drugs Market by Disease

• Market overview
• Dry Eye
  • Gels
  • Eye Solutions & Suspensions
  • Capsules & Tablets
  • Eye Drops
  • Ointments
• Allergies
  • Gels
  • Eye Solutions & Suspensions
  • Capsules & Tablets
  • Eye Drops
  • Ointments
• Glaucoma
  • Gels
  • Eye Solutions & Suspensions
  • Capsules & Tablets
  • Eye Drops
  • Ointments
• Infection
  • Gels
  • Eye Solutions & Suspensions
  • Capsules & Tablets
  • Eye Drops
  • Ointments
• Retinal disorders
  • Type
  • Macular Degeneration
  • Diabetic Retinopathy
  • Dosage Type
  • Gels
  • Eye Solutions & Suspensions
  • Capsules & Tablets
  • Eye Drops
  • Ointments
• Uveitis
  • Gels
  • Eye Solutions & Suspensions
  • Capsules & Tablets
  • Eye Drops
  • Ointments
• Others

Ophthalmic Drugs Market by Route of Administration

• Market overview
• Topical
• Local Ocular
  • Retinal Disorders
  • Subconjunctival
  • Intravitreal
  • Retrobulbar
  • Intracameral
• Systemic

Ophthalmic Drugs Market by Dosage Form

• Market Overview
• Gels
• Eye Solutions & Suspensions
• Capsules and Tablets
• Eye Drops
• Ointments

Ophthalmic Drugs Market by Type

• Market Overview
• Branded Drugs
• Generic Drugs

Ophthalmic Drugs Market by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon, Inc. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerie Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carl Zeiss Meditec AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Topcon Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Senju Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals, Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tarsus Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments